Life-Medea

Info for Patients

Life-Medea

Info for Patients

Life-Medea

Info for Patients

/

Info for patients

Asthmatic children

Asthmatic children will be invited to take part in a prospective study envisioned to provide the field-based evidence for the adoption of a strategic plan for mitigating the health effects of desert dust storm events in South-Eastern Europe. Children with asthma are particularly susceptible to the increase in dust particle levels from desert dust storm events. The asthmatic children who will participate in the program will be randomly divided into three groups. One group will receive notifications of upcoming desert dust events and guidelines on how to reduce outdoor exposure to dust particles (using smartphone devices), the second group will also receive notifications of upcoming desert dust storm events and guidelines on how to reduce both outdoor and indoor exposure to dust particles (using smartphone devices). The second group will also be provided with indoor air cleaners. The third group will not receive any notifications and no guidelines at all (control group).

All three groups of children will be assessed by experienced health professionals before, during, and after during the high DDS period. The Health Assessment includes a combination of telephone interviews (using the Asthma Control Test), assessments of lung function (Spirometry), fractional exhaled nitric oxide (FeNO), and specific aero-allergen sensitivities as well as recording changes in asthma medication and unscheduled hospital/clinical visits. This study does not include any type of medical intervention to the participants.

Patients with atrial fibrillation

Patients with atrial fibrillation that have been diagnosed with cardiac arrhythmias (atrial fibrillation) and have already dual chamber pacemakers implanted at least two months prior to randomization will be invited to take part in the study. A significant number of scientific studies have shown that patients with cardiovascular disease and more particularly patients with cardiac arrhythmias are very susceptible to the increase in dust particle levels from desert dust events. One group will receive notifications of upcoming desert dust events and guidelines on how to reduce outdoor exposure to dust particles (using smartphone devices), the second group will also receive notifications of upcoming desert dust storm events and guidelines on how to reduce both outdoor and indoor exposure to dust particles (using smartphone devices). The second group will also be provided with indoor air cleaners. The third group will not receive any notifications and no guidelines at all (control group).

All three groups of patients will be assessed by their physicians during hospital visits and heart arrhythmia events will be identified following downloading and analyzing the data stored in the patients’ pacemakers. Monthly telephone interviews will also be conducted focusing on symptoms of fatigue, changes in medication use, and unscheduled visits to health professionals for heart arrhythmia episodes. In addition continuous recordings of biological parameters (pulse rate, pulse rate variability) will be obtained by wearing smart watch sensors. This study does not include any type of medical intervention to the participants.

Data

Any personal data of participants that will be recorded during enrollment will be immediately transferred to the Patient Identification-Code (PID) system and a code for each patient will be created automatically. Disclosure of the patient's identity through PID will be impossible. Any information that concerns the patient will be strictly confidential and protected by the rules of medical confidentiality and the National Data Protection Laws. No personal data will be used in any of the publications of this project.

Copyrights © 2007-2018 All Rights Reserved by LIFE-Medea. Created by E.N.A CONSULTING